EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOMYG00000011075
Gene Symbol: NTRK2
1 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOMYG00000013330
Gene Symbol: NTRK2
1 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOMYG00000050545
Gene Symbol: NTRK3
1 Cross references
192 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOMYG00000048196
Gene Symbol: NTRK3
1 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSOMYG00000001377
Gene Symbol: NTRK1
2 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSOMYG00000005041
Gene Symbol: NTRK1
1 Cross references
193 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOMYG00000021208
Gene Symbol: NTRK2B
1 Cross references
204 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSOMYG00000035051
Gene Symbol: NTRK2B
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSOMYG00000039502
Gene Symbol: NTRK3A
1 Cross references
198 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSOMYG00000021434
Gene Symbol: NTRK3A
1 Cross references
198 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSOMYG00000024868
Gene Symbol: NFE2L2A
1 Cross references
199 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSOMYG00000023416
Gene Symbol: NFE2L2A
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).